Intarcia Therapeutics Stock

intarcia.comHealthcare / BioTech & PharmaFounded: 1995Funding to Date: $961.46MM

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Intarcia Therapeutics Stock Price

Forge Price 1
Price no longer available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Intarcia Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/15/2016 Series EE $475.68MM $xx.xx $3.94B Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group
Price per Share
$xx.xx
Shares Outstanding
14,166,667
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group
07/04/2014 Series DD $200MM $xx.xx $1.63B RA Capital, Fallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, Adams Street Partners, Fidelity Investments
Price per Share
$xx.xx
Shares Outstanding
6,174,746
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital, Fallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, Adams Street Partners, Fidelity Investments
11/15/2012 Series CC $210MM $xx.xx $612MM Venrock, New Leaf Venture Partners, New Enterprise Associates, Foresite Capital Management, Marker, The Baupost Group, Farallon Capital Management, Fidelity Investments
Price per Share
$xx.xx
Shares Outstanding
12,199,570
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock, New Leaf Venture Partners, New Enterprise Associates, Foresite Capital Management, Marker, The Baupost Group, Farallon Capital Management, Fidelity Investments
01/14/2010 Series BB-3 $7.87MM $xx.xx $138MM New Leaf Venture Partners, Venrock Associates, New Enterprise Associates
Price per Share
$xx.xx
Shares Outstanding
1,119,341
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Venrock Associates, New Enterprise Associates
04/28/2008 Series BB-2 $24.99MM $xx.xx $112MM New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
Price per Share
$xx.xx
Shares Outstanding
3,786,364
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
03/09/2007 Series BB-1 $23.84MM $xx.xx $103.02MM New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
Price per Share
$xx.xx
Shares Outstanding
3,974,119
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
12/01/2004 Series AA $19.08MM $xx.xx $98MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
3,180,135
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors

Intarcia Therapeutics stock FAQs

plusminus

Can you buy Intarcia Therapeutics stock?

You can no longer buy Intarcia Therapeutics stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Intarcia Therapeutics stock?

You can no longer buy Intarcia Therapeutics stock on a secondary marketplace as this company ceased its operations. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Intarcia Therapeutics stock?

You can no longer sell stock of Intarcia Therapeutics on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Intarcia Therapeutics stock?

You can no longer sell stock of Intarcia Therapeutics on Forge as this company ceased its operations. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Intarcia Therapeutics a public company?

Intarcia Therapeutics ceased its operations.
plusminus

What is Intarcia Therapeutics’ stock price?

Intarcia Therapeutics ceased its operations so there is no stock price available.
plusminus

What is Intarcia Therapeutics’ stock ticker symbol?

Intarcia Therapeutics ceased its operations so there is no stock ticker symbol.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Intarcia Therapeutics investors also invested in these private companies

Leadership & Board

Leadership

Paul Feldman, Ph.D.
Head of Discovery and Translational Medicine
David Spellman
Chief Business Officer and Chief Financial Officer
Thomas Alessi, Ph.D.
Vice President, Development and Manufacturing
Fred Fiedorek, M.D.
Chief Medical Officer and Global Head of Regulatory Affairs
Raymond Keane
Chief Legal Officer
Thane Wettig
Chief Commercial Officer
Jay Smith
Chief Experience Officer
Kurt Graves
Chairman, President & Chief Executive Officer
Anders Vinther, Ph.D
Global Head of Technical Operations
James Brady
Vice President, Human Resources
Andrew Young, M.B., Ch.B. (M.D.), Ph.D.
Chief Scientific Officer

Board

Bryan Roberts, Ph.D.
Venrock
Patrick Conway, MD
Kurt Graves
Nancy Thornberry
Bob Kerrey
Gino Santini
Jay S. Skyler, MD, MACP
Jim Rosenthal

Intarcia Therapeutics’ news and media highlights

The Diabetic Therapeutic Market  report  provides valuable and unique information which is very  essential. Further it also covers key players,application and future market condition.This information is extremely useful information for new and growing  company to mark themself over the market Diabetic Therapeutic market to grow at a CAGR OF 7.55% during the period 2017-2021. This …
LONDON, Nov. 16, 2016 /PRNewswire/ -- INTRODUCTIONPeptide therapeutics, due to their numerous advantages such as...
The Bill & Melinda Gates Foundation is investing as much as $140 million to support development of a tiny implantable drug pump it believes could help prevent people in sub-Saharan Africa and elsewhere from becoming infected with HIV, the virus that causes AIDS.
The Bill & Melinda Gates Foundation is investing up to $140 million to support development of a tiny implantable drug pump it believes could help prevent people in sub-Saharan Africa and elsewhere from becoming infected with HIV, the virus that causes AIDS.
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.